Trending: GSK Buys Bellus Health for About $2 Billion
18 Aprile 2023 - 12:30PM
Dow Jones News
0959 GMT - GSK is among the most mentioned companies across news
items over the past six hours, according to Factiva data, after it
said it had reached an agreement to buy Canadian late-stage
biopharmaceutical company Bellus Health Inc. for $14.75 a share in
cash, representing a total equity value of around $2.0 billion. The
British pharma major said that through the acquisition it will gain
access to camlipixant, a treatment for refractory chronic cough
which is currently in phase III development. Accretion to adjusted
earnings per share from the acquisition is expected to occur from
2027. It has the potential to deliver significant sales through
2031 and beyond, according to GSK. Dow Jones & Co. owns
Factiva. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
April 18, 2023 06:15 ET (10:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni BELLUS Health (NASDAQ:BLU)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni BELLUS Health (NASDAQ:BLU)
Storico
Da Mag 2023 a Mag 2024